Front. Transplant.Frontiers in TransplantationFront. Transplant.2813-2440Frontiers Media S.A.10.3389/frtra.2024.1476952TransplantationOriginal ResearchQuality of life, anxiety, and depression improve at one-year after liver transplantation in patients with advanced liver diseaseCordoba-AlvaradoRosana12Romero-FonnegraValentina3Cortes-MejiaNicolas24Bejarano-RamirezDiana Fernanda25Maldonado-HoyosValentina3Sanchez-GarciaSandra Janeth1Vera-TorresAlonso26*Clinical Psychology Section, Transplant Services, Fundacion Santa Fe de Bogotá, Bogotá, ColombiaTransplant and Hepatobiliary Surgery Department, Fundación Santa Fe de Bogotá, Bogotá, ColombiaFaculty of Psychology, Universidad de los Andes, Bogotá, ColombiaDivision of Anesthesiology Critical Care Medicine, and Pain Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United StatesEpidemiology and Biostatistics Group, Graduate School, Universidad CES, Medellín, ColombiaFaculty of Medicine, Universidad de los Andes, Bogotá, Colombia
Edited by: Linda Sher, University of Southern California, United States
Reviewed by: Luca Saverio Belli, Niguarda Ca' Granda Hospital, Italy
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
Background
Liver transplantation (LT) improves survival in end-stage liver disease. Several reports have addressed the impact of LT on patients’ lives, beyond purely medical outcomes. Although the quality of life and mental health have been demonstrated to improve with this procedure, such studies are still missing in Latin America.
Methods
Patients who received LT at the Fundación Santa Fe de Bogotá between 2017 and 2019 were assessed for quality of life (QoL), anxiety, and depression and they were followed up for one year after the procedure. Pre-transplant data were gathered at inclusion on the waiting list, while post-transplant data at 3- and 12 months after LT. European Quality of Life-5 Dimensions (EQ-5D) and European Quality of Life-Visual Analog Scale (EQ-VAS) instruments were used to evaluate QoL. The Hospital Anxiety and Depression Scale (HADS) was used for evaluating anxious and depressive symptoms.
Results
115 recipients met the inclusion criteria. Mean pre-transplant EQ-VAS was 70.78, rising to 87.16 and 92.56 at 3- and 12-months, respectively. Improvements in all EQ-5D dimensions were found in response to LT. According to the HADS questionnaire, anxiety was reduced by 2.35 points and depression by 1.63 points after LT.
Conclusion
in the short term, LT is a successful strategy for enhancing QoL, anxiety, and depression in patients with liver disease. Long-term benefits must be assessed.
quality of lifeEuropean Quality of Life-5 Dimensions (EQ-5D)European Quality of Life Visual Analog Scale (EQ-VAS)Hospital Anxiety and Depression Scale (HADS)liver transplantation (LT)Fundación Santa Fe de Bogota Transplant Departmentsection-at-acceptanceAbdominal TransplantationBackground
Chronic liver disease causes significant physical and psychological impairments secondary to the reduction of the synthetic and detoxifying functions of the liver, as well as complications from portal hypertension and long-lasting cholestasis (1). The likelihood of surviving without a liver transplant (LT) for patients with cirrhosis depends on disease severity, which is assessed using two systems: the MELD score and the Child-Pugh score (2). For instance, 96.5% ± 0.3% of patients with a MELD score below 15 survive for 90 days, while only 15.6% ± 2.5% survive with a score of 40 (3). This contrasts with the overall survival rates of LT recipients, which reach up to 94.4% at one year and 84.1% at five years post-procedure (4). The significant trend toward excellent survival rates has prompted transplant teams to focus not only on medical outcomes but also on ensuring that transplantation enhances patients’ quality of life (QoL) (5–7).
QoL is defined as an individual's perception of his position in life, framed within the set of cultural values in which he is immersed, and that closely defines his goals, expectations, norms, and concerns. It is a broad concept that comprehensively includes the person's physical and psychological health, beliefs, social relationships, and environmental interaction (8). Health-related QoL is based on self-reported physical and mental health measures, including the ability to be socially active (social well-being) (9). The QoL of cirrhotic patients is significantly lower than that of the general population (10–13). Patients with liver disease experience a reduced QoL due to the emotional and physical burdens of the disease. Additionally, psychiatric disorders such as anxiety and depression, along with the perception of frailty, often further impact patients’ QoL (14).
The impact of the transplantation on QoL has raised recent interest in the transplant community (15). Beginning with the waiting list, patients listed for a LT typically experience worsening physical and psychological health, which is further aggravated by the uncertainty of their transplant status (16, 17). However, while Casanovas et al. identified that QoL improvement becomes evident as early as three months after transplantation (13), Girgenti et al. reported that 94% of patients who underwent liver transplant (LT) described their QoL as excellent when considering factors such as physical well-being, physical symptoms, psychological symptoms, existential well-being, and support (18). These benefits seem to also be explained by an amelioration of the anxious and depressive symptoms in these patients (19, 20). Furthermore, a systematic review indicates that the QoL five years after transplantation is comparable to that of the general population. However, it is noteworthy that this improvement primarily relies on emotional and functional benefits rather than on physical improvement (21). Supporting the long-term benefits of transplantation, a study by Domingos et al. evaluating the QoL in Brazilian patients over ten years post-LT found that, except for the mental health domain, their scores were comparable to or higher than those of the general population (22).
In this context, this study aims to evaluate the impact of LT on QoL, anxiety, and depression in patients with liver disease, comparing these outcomes to their pre-transplant baseline. It also examines how these changes interact with disease severity and psychosocial factors present at the time of surgery.
MethodsDesign
All patients who underwent LT at the Fundación Santa Fe de Bogotá between 2017 and 2019 were screened for eligibility. A specialized psychology team followed the same operational standards to evaluate all LT candidates and their support networks at the time of their inclusion on the waiting list, and they conducted sequential follow-ups after the procedure. Only patients who were successfully followed up at three- and twelve-months post-transplantation were included. QoL along with symptoms of anxiety and depression, were retrospectively analyzed for changes. QoL surveys were conducted at 3- and 12-months post-procedure, while depression and anxiety symptoms were assessed only one year after the surgery.
Data collection instruments
Pre-transplant data were collected in person at the time of inclusion on the waiting list, while post-transplant data were obtained through in-person or telephone appointments. These evaluations aimed to assess patients’ understanding, beliefs, and commitment to the transplant process; identify psychosocial and emotional factors; evaluate adherence to medical treatments and healthy lifestyles; examine coping strategies; assess the quality of their support networks; and develop tailored action plans based on individual needs. The questionnaires used to assess patients’ QoL, as well as anxiety and depression, were delivered in a Spanish-validated version adapted to the Colombian context (23–27).
European Quality of Life-5 Dimensions (EQ-5D)
Developed in 1980, the EQ-5D is an instrument that assesses health-related QoL and has demonstrated validity for liver disease and post-LT period (28). From its conception, it was designed to be delivered both in person and via phone interviews (29). The EQ-5D measures the QoL by evaluating the following dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression (30–32).
European Quality of Life Visual Analog Scale (EQ-VAS)
The EQ-VAS is a component of the EQ-5D. It is a vertical scale ranging from 0 (worst imaginable health status) to 100 (best imaginable health status), allowing patients to quantitatively assess their overall health perception (23). Its validity for assessing the QoL in several conditions has been confirmed, making its application alongside the EQ-5D, appropriate for evaluating the QoL in cirrhotic patients and LT recipients (31, 32).
Hospital Anxiety and Depression Scale (HADS)
The HADS comprises 14 items (7 for anxiety and 7 for depression); each item is scored from 0 to 3. Scores from 0 to 7 indicate the absence of symptoms, scores from 8 to 10 suggest that the disease is probably present, whereas scores from 11 to 21 indicate the presence of anxiety or depression (25–27).
Statistical analysis
Categorical variables are described in terms of their frequency and percentage, and they were compared using the Chi-squared test. Continuous variables were assessed for normality using the Shapiro-Wilk test. Data exhibiting a parametric distribution were presented as the mean and standard deviation (SD), while those with a non-parametric distribution were displayed as the median and interquartile range (IQR). Depending on their distribution and whether the groups were related or independent, comparisons were made using the Wilcoxon test, Kruskal-Wallis test, and Mann-Whitney U-test. The level of statistical significance was set at p < 0.05, and analyses were conducted using Real Statistics v7.9 and SPSS v27 (IBM Corp.).
Ethical principles statement
This study was approved by the Fundación Santa Fe de Bogotá Corporate Committee for Ethics in Research (CCEI-15246-2023). A waiver of consent was provided as these surveys are part of the standard of care for LT recipients. Clinical data were obtained from the institution's electronic medical records, adhering to the principles of anonymity, privacy, and confidentiality. Access to the information was restricted solely to the researchers. The investigators attested that their conduct was aligned with the ethical principles of the Helsinki Declaration.
Results
Between 2017 and 2019, 129 patients underwent LT at our institution. Of these, 115 patients met the study criteria (Figure 1). The mean age was 58.6 ± 12 years, fifty-nine were male (51.0%), and fifty-six female (49.0%). Regarding disease severity, the majority had Child-Pugh B cirrhosis (53.0%), followed by Child-Pugh A (25.0%), and Child-Pugh C (17.0%) and 49.0% of patients had a MELD score of 15 or higher. These scores were not applied to 5 patients, as their transplants were indicated for acute hepatic failure rather than the management of cirrhosis. Autoimmune diseases were the leading cause of liver transplantation (30.4%), followed by non-alcoholic fatty liver disease (28.7%) and alcoholic hepatitis (18.3%). At the time of transplantation, 34 patients (29.6%) had a diagnosis of hepatocellular carcinoma. A comprehensive description of patient's demographic and psychosocial characteristics is shown in Table 1.
STROBE flow diagram illustrating the patient selection process.
Demographic and clinical characteristics.
Sex
n
%
Male
59
51.3%
Female
56
48.7%
Age
Mean ± SD
Min-Max
Overall
58.6 ± 12.0
16–76
Males
57.9 ± 12.6
16–75
Females
59.3 ± 11.3
24–76
Socioeconomic level
n
%
1
2
1.7%
2
29
25.2%
3
52
45.2%
4
26
22.6%
5
6
5.2%
Scholarship
n
%
None
2
1.7%
Incomplete elementary school
8
7.0%
Elementary school
11
9.6%
Incomplete baccalaureate
19
16.5%
Baccalaureate
23
20.0%
Technician
15
13.0%
Incomplete undergraduate
5
4.3%
Undergraduate
19
16.5%
Graduate
13
11.3%
Marital status
n
%
Marriage
48
41.74%
Free union
22
19.13%
Single
25
21.74%
Widowed
10
8.70%
Divorced
10
8.70%
Home tenancy
n
%
Leased
21
18.3%
Religious enclosure
1
0.9%
Family home
11
9.6%
Owned
82
71.3%
Occupation
n
%
Unemployed
1
0.9%
Working on profession
11
9.6%
Student
5
4.3%
Housekeeper
30
26.1%
Laid off
8
7.0%
Pensioner
21
18.3%
Employed
19
16.5%
Self-employed
20
17.4%
Child-Pugh score
n
%
N/A
5
4.3%
A
29
25.2%
B
61
53.0%
C
20
17.4%
MELD score
n
%
<15
59
51.3%
≥15
56
48.7%
Liver disease etiology
n
%
Alcoholic liver disease
21
18.3%
Autoimmune conditionsa
35
30.4%
Congenital conditionsb
5
4.3%
Pregnancy-associated acute hepatic failure
2
1.7%
Non-alcoholic fatty liver disease
33
28.7%
Secondary vascular/biliary cirrhosis
2
1.7%
Viral hepatitis
17
14.8%
Hepatocellular carcinoma
n
%
No
81
70.4%
Yes
34
29.6%
Including primary biliary cholangitis, primary sclerosing cholangitis, autoimmune hepatitis and cryptogenic hepatitis.
Including polycystic kidney disease, Wilson disease, Hemochromatosis and congenital hepatic fibrosis.
Quality of lifeEQ-VAS
The mean pre-LT QoL was 70.78 (SD = 17.9). It increased to 87.16 (SD = 13.61) at 3 months and to 92.56 (SD = 10.72) at 12 months post-transplant. The results compared across different time points were significant in all cases (p < 0.001) (Figure 2). Table 2 summarized the impact of the clinical and psychosocial variables on patients’ perception of their QoL evaluated through the EQ-VAS. None of these characteristics seems to have differentially impacted on patient's reported QoL.
Comparison between Pre- and post-transplant EQ-VAS scores. Self-reported QoL improves as early as 3 months after transplantation and the benefit is maintained and even enhanced at 12 postoperative months.
Effect of psychosocial and clinical variables on overall pre-transplant and 12-month post-transplant EQ-VAS.
Pre-transplant EQ-VAS
12-month post-transplant EQ-VAS
Median
IQR
p-value
Median
IQR
p-value
Age >65 years
78
60–90
0.216
95
90–100
0.414
Sex
Male
70
65–80
0.330
100
90–100
0.106
Female
70
60–80
93
90–100
Marital status
Marriage
76
60–85
0.574
98
90–100
0.308
Free union
70
60–90
100
90–100
Single
70
60–80
95
90–100
Widowed
65
50–75
93
90–100
Divorced
80
70–80
90
80–100
Scholarship
None
50
30–(-)
0.724
100
100–100
0.489
Incomplete elementary school
60
52.5–88.8
90
90–98.8
Elementary school
60
50–80
95
90–100
Incomplete baccalaureate
75
70–80
100
90–100
Baccalaureate
80
70–90
100
90–100
Technician
80
70–90
90
77.5–95
Incomplete undergraduate
50
25–77.5
85
90–100
Undergraduate
69
50–90
100
90–100
Graduate
80
67.5–80
50
30–70
Home tenancy
Owned
70
60–80
0.340
95
90–100
0.515
Leased
70
60–80
100
90–100
Family home
75
60–80
100
85–100
Religious enclosure
65
65–65
90
90–90
MELD score
≥15
69
55–80
0.227
100
90–100
0.170
Child–Pugh score
N/A
50
25–75
0.052
90
82.5–97.5
0.724
A
80
70–90
90.0–100.0
B
70
60–80
90.0–100.0
C
63
50–80
90.0–100.0
Liver disease etiology
Alcoholic liver disease
77
60–90
0.333
100
90–100
0.426
Autoimmune conditionsa
75
60–80
95
90–100
Congenital conditionsb
60
50–70
95
90–100
Pregnancy-associated acute hepatic failure
25
20–30
83
75–90
Non-alcoholic fatty liver disease
70
60–80
90
90–100
Secondary vascular/biliary cirrhosis
60
50–70
90
80–100
Viral hepatitis
70
60–90
100
90–100
Including primary biliary cholangitis, primary sclerosing cholangitis, autoimmune hepatitis and cryptogenic hepatitis.
Including polycystic kidney disease, Wilson disease, Hemochromatosis and congenital hepatic fibrosis.
EQ-5D
Table 3 illustrates patient progression in each component of the EQ-5D, from the pre-transplant evaluation to the assessments conducted at 3- and 12-months post-transplant.
Mobility: a significant improvement was observed in mobility between the pre-LT survey and 3- (p = 0.002) and 12 months post-transplant (p < 0.001) surveys; there was also a progressive improvement between the third and twelfth post-transplant months (p = 0.031).
Self-care: the capacity for self-care did not show significant improvement in the 3-month survey, but it did improve significantly in the 12-month post-transplant surveys compared to baseline (p = 0.126 and p = 0.043, respectively). Not significant improvement was seen between the third- and twelfth post-transplant surveys (p = 1.000).
Daily activities: patients reported an improvement when comparing pre-transplant surveys with 3- month and 12-month post-transplant surveys (p = 0.040 and p = 0.011, respectively), but no significant progression was seen between the two post-transplant questionnaires (p = 0.158).
Pain and discomfort: similarly, to the previous dimension, LT recipients reported an improvement when comparing pre-transplant surveys with both post-transplant surveys (p = 0.020 and p < 0.001, respectively), but no significant progression was seen between the two post-transplant timepoints (p = 0.107).
Anxiety and depression: the patients only demonstrated and improvement when comparing the pre-transplant surveys with the one-year post-transplant survey (p < 0.001). Improvement was also seen when compared the 3-month and the 12-month post-transplant reports (p = 0.031).
Comparison between pre-transplant and post-transplant EQ-5D dimensions.
Dimension
Pre-transplant
3 months post-transplant
12 months post-transplant
Pre-transplant vs. 3 months post-transplant
Pre-transplant vs. 12 months post-transplant
3 months post-transplant vs. 12 months post-transplant
n
%
n
%
n
%
p-value
p-value
p-value
Mobility
No problems
82
71%
104
90%
110
96%
0.002
<0.001
0.031
Some problems
29
25%
11
10%
5
4%
Unable to walk
4
3%
0
0%
0
0%
Self-care
No problems
100
87%
110
96%
114
99%
0.126
0.043
1.000
Some problems
12
10%
5
4%
1
1%
Unable to wash/dress
3
3%
0
0%
0
0%
Usual activities
No problems
71
62%
101
88%
108
94%
0.040
0.011
0.158
Some problems
36
31%
13
11%
7
6%
Unable to do usual activities
8
7%
1
1%
0
0%
Pain and discomfort
No pain/discomfort
55
48%
81
70%
93
81%
0.020
<0.001
0.107
Some pain/discomfort
57
50%
30
26%
21
18%
Extreme pain/discomfort
3
3%
4
3%
1
1%
Anxiety and depression
Not anxious/depressed
46
40%
92
80%
88
77%
0.055
<0.001
0.031
Moderate anxious/depressed
66
57%
20
17%
27
23%
Extremely anxious/depressed
3
3%
3
3%
0
0%
When analyzing each patient's progress across the dimensions (Supplementary Table S1), we found that out of the 29 patients who initially reported difficulties walking, 25 experienced symptom resolution by 12 months post-transplant (p = 0.031). Similarly, self-reported moderate anxiety and depression improved in 71.2% of cases, with extremely anxious or depressed patients showing significant improvement: 33.3% reported no problems, and 66.7% experienced at least moderate symptoms (p = 0.031). Furthermore, all 15 patients who reported self-care difficulties resolved their issues within a year post-transplant, although these differences were not statistically significant (p = 1.000). A comparable trend was observed in the dimension assessing usual activities, where only 11.4% of patients with reported issues and 12.5% of those unable to perform usual activities showed no change in their symptoms after one year (p = 0.158). Pain and discomfort also demonstrated improvement, with only 24.6% of patients reporting some pain and discomfort, and 33.3% experiencing extreme pain and discomfort, persisting at the 12-month mark. Supplementary Table S1 provides a more detailed analysis of each patient's progress across the various dimensions of the EQ-5D at different time points.
Anxiety and depressionHADS
Figure 3 depicts the overall anxiety and depression scores yielded by the HADS questionnaire. For anxiety, a mean difference of 2.35 ± 3.02 points was observed between the pre-transplant (5.10 ± 3.20) and post-transplant (2.75 ± 2.35) measurements. Regarding depressive symptoms, a mean difference of 1.63 ± 2.76 points was observed between the two periods (3.09 ± 2.72 and 1.46 ± 1.75, respectively). In all the scenarios the differences were statistically significant (p < 0.001). Table 4 displays how the clinical and psychosocial baseline characteristics interact with the overall HADS score during both pre-transplant and post-transplant stages. In this analysis, it was shown that females achieved up to three times more abnormal HADS score when compared to males during the pre-transplant stage (30.9% vs. 11.1%, p = 0.001), although this difference disappeared after receiving the transplant (1.8% vs. 0.9%, p = 0.612). Contrary to what it could be expected, patients who presented alcoholic liver disease did not have a markedly proportion of abnormal HADS scores compared to other etiologies like autoimmune conditions or the viral hepatitis (3.7% vs. 16.0% and 9.9%, respectively, p = 0.030). Moreover, a significant improvement from abnormal to normal scores after the transplant was seen in patients with decompensated Child-Pugh B/C liver disease.
Changes in pre-transplant anxiety and depression according to the HADS tool at 12 months after LT. For both categories, a significant decrease was obtained with the LT.
Effect of psychosocial and clinical variables on overall pre- and post-transplant HADS score.
Pre-transplant HADS
12-month post-transplant HADS
Normal
%
Abnormal
%
p-value
Normal
%
Abnormal
%
p-value
81
100.0%
34
42.0%
112
100.0%
3
2.7%
Age >65 years
32
39.5%
12
14.8%
0.682
42
37.5%
2
1.8%
0.557
Sex
Male
50
61.7%
9
11.1%
0.001
58
51.8%
1
0.9%
0.612
Female
31
38.3%
25
30.9%
54
48.2%
2
1.8%
Marital status
Marriage
36
44.4%
12
14.8%
0.116
46
41.1%
2
1.8%
0.453
Free union
13
16.0%
9
11.1%
22
19.6%
0
0.0%
Single
20
24.7%
5
6.2%
25
22.3%
0
0.0%
Widowed
4
4.9%
6
7.4%
10
8.9%
0
0.0%
Divorced
8
9.9%
2
2.5%
9
8.0%
1
0.9%
Scholarship
None
1
1.2%
1
1.2%
0.515
2
1.8%
0
0.0%
0.559
Incomplete elementary school
6
7.4%
2
2.5%
8
7.1%
0
0.0%
Elementary school
7
8.6%
4
4.9%
11
9.8%
0
0.0%
Incomplete baccalaureate
10
12.3%
9
11.1%
19
17.0%
0
0.0%
Baccalaureate
17
21.0%
6
7.4%
21
18.8%
2
1.8%
Technician
13
16.0%
2
2.5%
15
13.4%
0
0.0%
Incomplete undergraduate
3
3.7%
2
2.5%
5
4.5%
0
0.0%
Undergraduate
13
16.0%
6
7.4%
19
17.0%
0
0.0%
Graduated
11
13.6%
2
2.5%
12
10.7%
1
0.9%
Home tenancy
Owned
57
70.4%
25
30.9%
0.769
79
70.5%
3
2.7%
1.000
Leased
14
17.3%
7
8.6%
21
18.8%
0
0.0%
Family home
9
11.1%
2
2.5%
11
9.8%
0
0.0%
Religious enclosure
1
1.2%
0
0.0%
1
0.9%
0
0.0%
MELD Score ≥15
46
56.8%
15
18.5%
0.227
59
52.7%
2
1.8%
1.000
Child-Pugh score
N/A
3
3.7%
2
2.5%
0.352
4
3.6%
1
0.9%
0.021
A
24
29.6%
5
6.2%
27
24.1%
2
1.8%
B
41
50.6%
20
24.7%
61
54.5%
0
0.0%
C
13
16.0%
7
8.6%
20
17.9%
0
0.0%
Liver disease etiology
Alcoholic liver disease
18
22.2%
3
3.7%
0.030
21
18.8%
0
0.0%
0.433
Autoimmune conditionsa
22
27.2%
13
16.0%
35
31.3%
0
0.0%
Congenital conditionsb
4
4.9%
1
1.2%
5
4.5%
0
0.0%
Pregnancy-associated acute hepatic failure
1
1.2%
1
1.2%
2
1.8%
0
0.0%
Non-alcoholic fatty liver disease
27
33.3%
6
7.4%
31
27.7%
2
1.8%
Secondary vascular/biliary cirrhosis
0
0.0%
2
2.5%
2
1.8%
0
0.0%
Viral hepatitis
9
11.1%
8
9.9%
16
14.3%
1
0.9%
Including primary biliary cholangitis, primary sclerosing cholangitis, autoimmune hepatitis and cryptogenic hepatitis.
Including polycystic kidney disease, Wilson disease, Hemochromatosis and congenital hepatic fibrosis.
When the results are categorized as normal, borderline, and abnormal, it was observed that the percentage of patients scoring within the normal range on the HADS questionnaire increased from 43.8% in the pre-transplant stage to 80.9% in the post-transplant stage (p < 0.001). Notably, there was a significant improvement in the anxiety questionnaire, where the percentage of patients reporting normal levels raised from 76.5% before the liver transplantation to 95.7% afterward (p < 0.001) (Table 5).
Overall, anxiety and depression pre-transplant and post-transplant HADS scores.
HADS Categories
Overall HADS
Anxiety HADS
Depression HADS
Pre-transplant
12 months after transplant
Pre-transplant
12 months after transplant
Pre-transplant
12 months after transplant
n
%
n
%
p-value
n
%
n
%
p-value
n
%
n
%
p-value
Normal (0–7)
55
43.8%
93
80.9%
<0.001
88
76.5%
110
95.7%
<0.001
108
93.9%
114
99.1%
<0.001
Borderline (8–10)
26
22.6%
19
16.5%
21
18.3%
4
3.5%
6
5.2%
1
0.9%
Abnormal (11–21)
34
23.6%
3
2.6%
6
5.2%
1
0.9%
1
0.9%
0
0.0%
Table 6 displayed in a more detailed way how all the individuals progressed between the two timepoints. These improvements become evident when we examine each patient's progress. For instance, among the 26 patients with a borderline overall HADS score, 73.1% achieved normal scores one-year post-transplant, while 7.7% experienced a decline. A more significant improvement was noted in the 22 patients with abnormal pre-transplant HADS scores: 64.7% moved from an abnormal to a normal score, and 32.4% improved to a borderline score, with only one patient showing no improvement (p = 0.001). Analyzing the HADS anxiety questionnaire reveals that all patients with abnormal scores and 81.0% of those with borderline scores achieved normal results after the transplant (p = 0.013). Furthermore, all patients who initially scored as borderline or abnormal on the HADS depression questionnaire reported normal scores one-year post-transplant, with only one patient who was previously normal now showing a borderline score.
Patient progression in the HADS score before and after liver transplantation.
Pre-transplant
12-months post-transplant
Normal
Borderline
Abnormal
n
%
n
%
n
%
p-value
HADS overall
Normal
52
94.5%
3
5.5%
0
0.0%
0.001
Borderline
19
73.1%
5
19.2%
2
7.7%
Anormal
22
64.7%
11
32.4%
1
2.9%
HADS anxiety
Normal
87
98.9%
1
1.1%
0
0.0%
0.013
Borderline
17
81.0%
3
14.3%
1
4.8%
Anormal
6
100.0%
0
0.0%
0
0.0%
HADS depression
Normal
107
99.1%
1
0.9%
0
0.0%
(-)
Borderline
6
100.0%
0
0.0%
0
0.0%
Anormal
1
100.0%
0
0.0%
0
0.0%
Discussion
As the number of LTs increases and the survival rate improves, recent studies are focusing on the evaluation of secondary outcomes beyond purely medical results. How this procedure affects all aspects of a patient's life is a topic of high interest to the transplantation community. This study retrospectively analyzed the QoL, and the anxious and depressive symptoms in a cohort of patients undergoing LT and compared their scores with their pre-transplant baselines.
Being part of an LT program has been shown to provide benefits beyond purely medical outcomes related to liver disease; it also improves the management of other chronic conditions by ensuring timely access to various medical specialties. In Brazil, Bastos et al. found that transplantation not only significantly improved liver-related symptoms, but also other social aspects, disease-related concerns, sexual function, and sleep quality (33). In Turkey, Tamer M. and Yava A. explored the QoL in 103 LT recipients; they concluded that LT had a positive impact on recipients’ QoL and functionality, despite the need for compliance for several medical appointments that this procedure induces and the LT-related complications (34).
Our study provides insights into how LT affects QoL in a Latin American context. We found that the QoL according to the EQ-5D improves when a patient with chronic liver disease receives a LT. This benefit is kept in all the dimensions that are evaluated by this instrument. However, we found that the improvement is not evenly distributed over time, and that LT affects each dimension differently. These findings are consistent with similar studies conducted globally over the past decade (13, 15, 21, 35).
In previous reports, several demographic factors were associated with the QoL in transplant recipients, including marital status, age, gender, and occupation (15, 35, 36). Like in the general population, older patients are expected to have a decline in their QoL (37). It has also been described that LT recipients who remained employed demonstrated better QoL compared to those who were not employed (37). In terms of gender, women often report a significantly lower QoL after LT compared to men (38), although this is not always supported in all the studies (15). Regarding marital status, Mendoza-Sanchez et al. concluded that this variable does not significantly affect the QoL in LT recipients (35). In our study, we found that males and females were homogenously represented, and most were between 50 and 70 years of age. Concerning the sociodemographic characteristics, many were part of the lower-middle class according to Colombian income classification. In our setting, this is typically associated with incomplete education. Most of the patients were married, the majority owned their homes, and most were engaged in household duties. We found no significant differences in QoL across these variable categories.
The EQ-VAS analysis quantified the impact of LT on QoL. In general, a significant improvement in response to transplantation was found. We did not find any differences in this measurement between men and women during the pre-transplant period. However, at three months post-transplant, while both genders reported an enhanced QoL, women had a lower improvement compared to men. These findings are similar to those found by Cowling et al. (38). Interestingly, these differences seem to disappear twelve months after the procedure, supporting Dąbrowska-Bender et al.'s findings (15).
Interestingly, a higher MELD score did not necessarily correlate with poorer QoL, but some were observed when using the Child-Pugh score. This effect was previously described by Cristin et al. and Rabiee et al. (14, 39). These authors explain that this discrepancy happens because the MELD score does not account for symptoms associated with poorer QoL such as encephalopathy and ascites, whereas the Child Pugh score does. Importantly, our population of transplanted patients predominantly suffered from autoimmune conditions, which collectively accounted for nearly one-third of the studied cohort. This was closely followed by cases of non-alcoholic steatohepatitis. Patients with alcoholic liver disease constituted less than one-fifth of the population. This distribution differs from the patterns typically observed in other studies. The potential impact of this pattern on patient-reported QoL should be explored in future studies.
We also found a significant improvement in anxious and depressive symptoms after LT supporting the results of Mejia et al. and Martin-Rodriguez et al. (20, 35). These findings demonstrate that LT has also a positive impact on the emotional health of patients with liver disease. Of note, females had more frequently abnormal HADS scores in the pre-transplant setting similarly to what was described by Dąbrowska-Bender et al. (15), although these differences were ameliorated at twelve months post-procedure. Moreover, an inverse relationship between anxiety and depression levels and QoL was found, both at three- and twelve months post-transplant, as measured by HADS and EQ-5D. This highlights the significant role of psychological health on overall health perception beyond medical issues in LT recipients, as stated by Rabiee et al. (14).
Finally, it's important to note that instruments like the EQ-5D and the HADS primarily serve as supplementary diagnostic tools rather than definitive assessments. They should not replace a thorough psychological or psychiatric evaluation by a skilled team. Moreover, these instruments differ in their performance at detecting symptoms of anxiety and depression as the EQ-5D relies on a single self-reported question, while the HADS provides a more comprehensive evaluation of anxious and depressive symptoms.
Future perspectives
Although this and several other studies have assessed short-term QoL in LT recipients, the impact of this intervention over more extended periods remains uncertain. More studies evaluating the QoL and mental health at 3, 5, and 10 years after LT might reveal the true impact of this procedure on patients’ lives and their reintegration into daily activities. These results may also guide transplant teams to intervene in these indicators. Finally, exploring other aspects of QoL beyond those evaluated by the EQ-5D could be worthwhile. Those aspects may include sexual function and other psychosocial factors (21).
Limitations
Although QoL questionnaires have been validated for liver disease and transplantation, they are not specific to this condition, and important factors affecting QoL in these patients may have been overlooked. While there are questionnaires specifically designed for cirrhotic patients, they have yet to be validated for use in the Latin American context. Despite efforts to address several variables impacting QoL, not all could be explored, including those related to post-transplant medical conditions and medications. Therefore, confounding variables should be examined more thoroughly in future studies. Lastly, data from patients who died, were lost to follow-up, or could not be evaluated due to their medical condition were not included in the analysis.
Conclusions
The medical advancements of the last two decades have rendered LT a safe procedure for the management of chronic liver disease. Consequently, outcomes beyond mere survival must be measured to gauge the impact of transplantation on these individuals. In this context, this study demonstrated that, at least in the short term, LT is a successful strategy for enhancing the QoL of LT recipients. Our results support that in Latin America LT improves the QoL and mental health of the patients, as described in other regions. Special attention and follow-up by the medical, paramedical, and psychological teams must be ensured for women and patients displaying anxious or depressive symptoms, as these subgroups demonstrated less significant improvements in terms of QoL. Timely interventions might enhance this indicator.
Data availability statement
The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.
Ethics statement
The studies involving humans were approved by Mieth, Klaus; Moreno, Bernardo; Quijano, Diana; Rojas, Jorge; Perdomo, Carlos; Gonzales, Margarita; Palacio, Ana; Santamaría, Eugenia; Caro, Angela; Galvis, Katherine; Garcia, Gloria; Camacho, Maria; Holguin, Lope. The studies were conducted in accordance with the local legislation and institutional requirements. The ethics committee/institutional review board waived the requirement of written informed consent for participation from the participants or the participants’ legal guardians/next of kin because Due to the retrospective nature of the study. All the data was collected per clinical protocol as part of the liver transplantation process.
The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was supported by the Fundación Santa Fe de Bogotá Transplant Department through internal resources.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Supplementary material
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/frtra.2024.1476952/full#supplementary-material
Abbreviations
EQ-5D, European Quality of Life-5 Dimensions; EQ-VAS, European Quality of Life Visual Analog Scale; HADS, Hospital Anxiety and Depression Scale; LT, liver transplantation; QoL, quality of life.
ReferencesPérez-San-GregorioMÁMartín-RodríguezADomínguez-CabelloEFernández-JiménezEBernardos-RodríguezÁ. Quality of life and mental health comparisons among liver transplant recipients and cirrhotic patients with different self-perceptions of health. J Clin Psychol Med Settings. (2013) 20(1):97–106. 10.1007/s10880-012-9309-0PengYQiXGuoX. Child-Pugh versus MELD score for the assessment of prognosis in liver cirrhosis: a systematic review and meta-analysis of observational studies. Medicine (Baltimore). (2016) 95(8):e2877. 10.1097/MD.000000000000287726937922VanDerwerkenDNWoodNLSegevDLGentrySE. The precise relationship between model for end-stage liver disease and survival without a liver transplant. Hepatology. (2021) 74(2):950–60. 10.1002/hep.3178133655565Service NH. Annual Report on Liver Transplantation. Available online at:https://nhsbtdbe.blob.core.windows.net/umbraco-assets-corp/24593/nhsbt-liver-transplant-report-2021-final.pdf2021 (accessed January 23, 2024).BurraPGermaniG. Long-term quality of life for transplant recipients. Liver Transpl. (2013) 19(S2):S40–3. 10.1002/lt.2372523960031BravataDMKeeffeEB. Quality of life and employment after liver transplantation. Liver Transpl. (2001) 7(11B):s119–23. 10.1053/jlts.2001.2852011689784TomeSWellsJTSaidALuceyMR. Quality of life after liver transplantation. A systematic review. J Hepatol. (2008) 48(4):567–77. 10.1016/j.jhep.2007.12.01318279999HaraldstadKWahlAAndenaesRAndersenJRAndersenMHBeislandEA systematic review of quality of life research in medicine and health sciences. Qual Life Res. (2019) 28(10):2641–50. 10.1007/s11136-019-02214-931187410KondoYYoshidaHTateishiRShiinaSMineNYamashikiNHealth-related quality of life of chronic liver disease patients with and without hepatocellular carcinoma. J Gastroenterol Hepatol. (2007) 22(2):197–203. 10.1111/j.1440-1746.2006.04456.x17295871SaabS. Evaluation of the impact of rehospitalization in the management of hepatic encephalopathy. Int J Gen Med. (2015) 8:165–73. 10.2147/IJGM.S8187825999756BownikHSaabS. Health-related quality of life after liver transplantation for adult recipients. Liver Transpl. (2009) 15(S2):S42–9. 10.1002/lt.2191119876941StineJGStukenborgGJWangJAdkinsANiccumBZimmetALiver transplant candidates have impaired quality of life across health domains as assessed by computerized testing. Ann Hepatol. (2020) 19(1):62–8. 10.1016/j.aohep.2019.06.01831558420CasanovasTHerdmanMChandiaAPenaMCFabregatJVilallongaJS. Identifying improved and non-improved aspects of health-related quality of life after liver transplantation based on the assessment of the specific questionnaire liver disease quality of life. Transplant Proc. (2016) 48(1):132–7. 10.1016/j.transproceed.2015.11.00926915858RabieeAXimenesRONikayinSHicknerAJuthaniPRosenRHFactors associated with health-related quality of life in patients with cirrhosis: a systematic review. Liver Int. (2021) 41(1):6–15. 10.1111/liv.1468032998172Dąbrowska-BenderMKozaczukAPączekLMilkiewiczPSłoniewskiRStaniszewskaA. Patient quality of life after liver transplantation in terms of emotional problems and the impact of sociodemographic factors. Transplant Proc. (2018) 50(7):2031–8. 10.1016/j.transproceed.2018.03.113SinclairMPoltavskiyEDodgeJLLaiJC. Frailty is independently associated with increased hospitalisation days in patients on the liver transplant waitlist. World J Gastroenterol. (2017) 23(5):899–905. 10.3748/wjg.v23.i5.89928223735StewartKEHartRPGibsonDPFisherRA. Illness apprehension, depression, anxiety, and quality of life in liver transplant candidates: implications for psychosocial interventions. Psychosomatics. (2014) 55(6):650–8. 10.1016/j.psym.2013.10.00224360533GirgentiRTropeaAButtafarroMARagusaRAmmirataM. Quality of life in liver transplant recipients: a retrospective study. Int J Environ Res Public Health. (2020) 17(11):3809. 10.3390/ijerph1711380932471157Martín-RodríguezAPérez-San-GregorioMADomínguez-CabelloEFernández-JiménezEBernardos-RodríguezÁ. Funcionamiento biopsicosocial entre pacientes cirróticos en distin-tas etapas del proceso de trasplante y su comparación con trasplantados hepáticos. An Psicol. (2014) 30(1):83–92. 10.6018/analesps.30.1.148241Moreno-MedinaKGómezMTMejíaG. Evaluación de la calidad de vida relacionada con la salud pre y post trasplante hepático, en pacientes de un hospital de alta complejidad. Psychologia. (2019) 13(1):65–72. 10.21500/19002386.3721YangLSShanLLSaxenaAMorrisDL. Liver transplantation: a systematic review of long-term quality of life. Liver Int. (2014) 34(9):1298–313. 10.1111/liv.1255324703371DomingosMFCoelhoJCUNogueiraIRParolinMBMatiasJEFDe FreitasACTQuality of life after 10 years of liver transplantation. J Gastrointestin Liver Dis. (2020) 29(4):611–6. 10.15403/jgld-282933118544HerdmanMBadiaXBerraS. EuroQol-5D: a simple alternative for measuring health-related quality of life in primary car. Aten Primaria. (2001) 28(6):425–30. 10.1016/S0212-6567(01)70406-411602124BaileyHHJanssenMFVarelaROMorenoJA. EQ-5D-5l population norms and health inequality in Colombia. Value Health Reg Issues. (2021) 26:24–32. 10.1016/j.vhri.2020.12.00233773292Cassiani-MirandaCAScoppettaOCabanzo-ArenasDF. Validity of the hospital anxiety and depression scale (HADS) in primary care patients in Colombia. Gen Hosp Psychiatry. (2022) 74:102–9. 10.1016/j.genhosppsych.2021.01.01433750606HinzAFinckCGómezYDaigIGlaesmerHSingerS. Anxiety and depression in the general population in Colombia: reference values of the hospital anxiety and depression scale (HADS). Soc Psychiatry Psychiatr Epidemiol. (2014) 49(1):41–9. 10.1007/s00127-013-0714-y23748887JavierLRicoMRMolinaM. Adapatacion y validacion de la escala hospitalaria de ansiedad y depresion (HAD) en una muestra de pacientes con cancer del instituto nacional de cancerologia de Colombia. Av Med. (2005) 3:73–86.Cano GutiérrezCArciniegas RubioAGermán BordaMSamper-TernentRGil LaverdeFLondoño TrujilloD. Perception of health-related quality of life using the EURO-QOL in older adults in Bogotá, Colombia. Eur Geriatr Med. (2016) 7(4):340–5. 10.1016/j.eurger.2016.01.008McPhailSLanePRussellTBrauerSGUrrySJasiewiczJTelephone reliability of the Frenchay activity Index and EQ-5D amongst older adults. Health Qual Life Outcomes. (2009) 7:48. 10.1186/1477-7525-7-4819476656DevlinNJBrooksR. EQ-5D and the EuroQol group: past, present and future. Appl Health Econ Health Policy. (2017) 15(2):127–37. 10.1007/s40258-017-0310-528194657JanssenMFLubetkinEISekhoboJPPickardAS. The use of the EQ-5D preference-based health status measure in adults with type 2 diabetes mellitus. Diabetic Med. (2011) 28(4):395–413. 10.1111/j.1464-5491.2010.03136.x21392061JohnsonJACoonsSJ. Comparison of the EQ-5D and SF-12 in an adult US sample. Qual Life Res. (1998) 7(2):155–66. 10.1023/A:10088096107039523497BastosKXFreire de AguiarMIGarciaJHPDourado ArraisPS. Quality of life and liver transplant: a comparative evaluation between different post-transplant phases. J Young Pharm. (2023) 15(1):167–73. 10.5530/097515050491TamerMYavaA. The quality of life of patients after liver transplantation. Ann Med Res. (2022) 29(2):139–43. 10.5455/annalsmedres.2021.04.366Mendoza-SánchezFRamírez-GonzálezLRReyes-CruzAAGonzález-OjedaAHernández-MachucaJSFuentes-OrozcoC. Evaluacion de la calidad de vida en pacientes en pacientes con trasplante hepatico. Rev Med Inst Mex Seguro Soc. (2016) 54(2):176–81.AguiarMIBragaVAGarciaJHLimaCAAlmeidaPCSouzaAMQuality of life in liver transplant recipients and the influence of sociodemographic factors. Rev Esc Enferm USP. (2016) 50(3):411–8. 10.1590/S0080-62342016000040000627556711KotarskaKWunschEKempinska-PodhorodeckaARaszeja-WyszomirskaJBogdanosDPWojcickiMFactors affecting health-related quality of life and physical activity after liver transplantation for autoimmune and nonautoimmune liver diseases: a prospective, single centre study. J Immunol Res. (2014) 2014:738297. 10.1155/2014/73829724741621CowlingTJenningsLWGoldsteinRMSanchezEQChinnakotlaSKlintmalmGBLiver transplantation and health-related quality of life: scoring differences between men and women. Liver Transpl. (2004) 10(1):88–96. 10.1002/lt.2001314755784CristinDJFormanLMJacksonWE. Beyond survival: targeting health-related quality of life outcomes after liver transplantation. Clin Liver Dis (Hoboken). (2021) 17(5):359–64. 10.1002/cld.105934136142